Overview of Dr. Desancho
I am a board certified hematologist specialized in thrombosis and hemostasis with special interest in pregnant women with thrombotic and bleeding disorders.
In addition I follow a large group of patients with venous thrombosis and provide advice on type of anticoagulation, indications for thrombophilia screening and duration of anticoagulation.
One of my goals is to optimize the transition of care (TOC) of patients diagnosed from venous thromboembolism (VTE) from the inpatient to the outpatient setting. To achieve this goal I am participating with 15 other Hemostasis Thrombosis centers across the US on an ongoing quality improvement project to optimize the TOC of both pediatric and adult patients with a first diagnosis of VTE from the inpatient to the outpatient setting.
Another area of interest is to evaluate mechanisms of thrombosis in cancer patients, and create and algorithm based on clinical and current and novel laboratory data that can predict the risk of thrombosis in cancer patients.
Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021
Education & Training
- Weill Cornell Medical CollegeM.S.c, Clinical Sciences, 2005 - 2009
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1995 - 1996
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1992 - 1995
- New York Medical College (Metropolitan)Residency, Internal Medicine, 1987 - 1991
- Autonomous University of Madrid Class of 1983
Certifications & Licensure
- NY State Medical License 1996 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) Start of enrollment: 2013 Jan 31
- Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Start of enrollment: 2020 Oct 13
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study.Wilma Barcellini, Fabrizio Pane, Andrea Patriarca, Irina Murakhovskaya, Louis Terriou
American Journal of Hematology. 2024-12-01 - Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network.Maria T DeSancho, Erin Suvar, Jonathan C Roberts, Michael D Tarantino, Jonathan Schwartz
Journal of Thrombosis and Haemostasis. 2024-11-01 - ASH living guidelines on use of anticoagulation for thromboprophylaxis in patients with COVID-19: executive summary.Deborah M Siegal, Eric K Tseng, Holger J Schünemann, Pantep Angchaisuksiri, Adam Cuker
Blood Advances. 2024-10-22
Journal Articles
- Delayed diagnosis of congenital sideroblastic anemiaGhaith Abu-Zeinah,MD, Maria T.DeSancho,MD,MSc, Mustafa Al-Kawaaz,MD Julia Geyer,MD, Seminars inHematology ], 11/2018
Committees
- Co-Chair Thrombosis Committee, American Thrombosis Hemostasis Network 2015 - 2017
Professional Memberships
- Member
- International Society of Thrombosis and HaemostasisMember
Other Languages
- Spanish
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: